胰岛素样生长因子2 mRNA结合蛋白2 是卵巢癌的治疗点
Jia Yuan1,2, Xin Li1,2, Fanchen Wang1,2
1Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, 1508 Longhang Road, Shanghai 201508, China.
Experimental biology and medicine (Maywood, N.J.)
|December 12, 2023
概括
胰岛素样生长因子2 mRNA结合蛋白2 (IGF2BP2) 在卵巢癌 (OC) 中过度表达,推动细胞生长. 向IGF2BP2可能为OC患者提供新的治疗和诊断策略,可能改善免疫治疗反应.
科学领域:
- 妇科瘤学 妇科瘤学
- 分子生物学分子生物学
- 癌症基因组学 癌症基因组学
背景情况:
- 卵巢癌 (OC) 是癌症死亡的首要原因,由于化学抗药性而经常复发.
- 对OC的有效治疗点和生物标志物仍然至关重要.
研究的目的:
- 研究胰岛素样生长因子2 mRNA结合蛋白2 (IGF2BP2) 在卵巢癌中的作用和临床意义.
- 评估IGF2BP2作为OC的潜在治疗标和诊断生物标志物.
主要方法:
- 在OC组织和细胞中进行IGF2BP2表达分析的定量实时PCR和西布洛特.
- 对TCGA,CPTAC,GEO和CCLE数据库进行IGF2BP2表达和临床相关性的分析.
- 用于功能探索的GSEA,KEGG和GO分析;用于扩散评估的细胞计数工具-8测定.
- 使用"pRophetic"和TCIA对化疗抵抗和免疫治疗反应的生物信息分析.
主要成果:
- 在OC中,IGF2BP2mRNA和蛋白质表达显著上调.
- 部分是由于基因组放大而导致的IGF2BP2过度表达,与生存率差和STAT1表达相关.
- 抑制IGF2BP2抑制了OC细胞的增殖.
- 低IGF2BP2表达与化学抵抗有关,但瘤免疫透率较高,这表明免疫治疗的潜力.
结论:
- IGF2BP2是OC细胞增殖的关键驱动因素,与患者不良结果有关.
- IGF2BP2表达水平可以预测化疗和免疫疗法的反应.
- IGF2BP2是一个有前途的治疗标和卵巢癌的诊断生物标志物.
更多相关视频
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
903
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.8K
相关概念视频
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K